SCHEMBL30775172

SCHEMBL30775172

O=C1NCc2c1cccc2-c1cnc(N2CCNCC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ PIK3CD O00329 2/20 0.43
▸ PIK3CA P42336 2/20 0.43
▸ PIK3CB P42338 2/20 0.43
▸ PIK3CG P48736 1/20 0.43
▸ TAAR1 Q96RJ0 1/20 0.43
▸ FEN1 P39748 1/20 0.43
▸ CDK5 Q00535 2/20 0.42
▸ DYRK1A Q13627 2/20 0.42
▸ CLK4 Q9HAZ1 2/20 0.42
▸ PIM1 P11309 1/20 0.42
▸ CSNK1A1 P48729 1/20 0.42
▸ ROCK1 Q13464 1/20 0.42
▸ LRRK2 Q5S007 1/20 0.42
▸ DYRK1B Q9Y463 1/20 0.42
▸ LTK P29376 1/20 0.41
▸ MST1R Q04912 1/20 0.41
▸ KDR P35968 2/20 0.41
▸ ACVR1 Q04771 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775275 0.80 PRKD1 (0.48) PIK3CDPIK3CAPIK3CBDYRK1APRKD1
SCHEMBL30843943 0.76 CDK5 (0.50) KDM4EALDH1A1CDK5DYRK1ACLK4
SCHEMBL2346037 0.76 CDK5 (0.50) KDM4EALDH1A1CDK5DYRK1ACLK4
SCHEMBL30775183 0.73 CLK4 (0.53) PIK3CDPIK3CAPIK3CBPIK3CGCDK5
SCHEMBL30775345 0.73 PIK3CD (0.49) PIK3CDPIK3CAPIK3CBPIK3CGCDK5
SCHEMBL30913134 0.72 PRKD1 (0.51) PRKD1
SCHEMBL30775359 0.72 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPIK3CGCDK5
SCHEMBL30775209 0.72 CNR2 (0.58) ALDH1A1KDRCNR2
SCHEMBL9685225 0.71 MKNK2 (0.51) KDM4EALDH1A1TAAR1
SCHEMBL9400977 0.70 TAAR1 (0.64) KDM4EALDH1A1TAAR1KDRACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 — — US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 — — US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR KDM4E 4591/4885ALDH1A1 3927/4885PIK3CD 1653/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR KDM4E 4591/4885ALDH1A1 3927/4885PIK3CD 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback